Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status

• Published in: International journal of molecular sciences Vol. 24; no. 20; p. 15179
• Main Authors: Wu, Qiong, Berglund, Anders E, Macaulay, Robert J, Etame, Arnold B
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2023; MDPI
• Subjects: 5-Aza; Animals; Brain cancer; Cancer therapies; Datasets; DNA methylation; Enzymes; Epigenetic inheritance; Epigenetics; GBM; Genes; Glioma; glioma stem cell; Methylation; MGMT; Patients; Protein expression; Proteins; Stem cells; Survival analysis; Temozolomide; TMZ; Transferases; Tumors; Massachusetts; California

Temozolomide (TMZ) is an important first-line treatment for glioblastoma (GBM), but there are limitations to TMZ response in terms of durability and dependence on the promoter methylation status of the DNA repair gene O6-methylguanine DNA methyltransferase (MGMT). MGMT-promoter-hypermethylated (MGMT...